Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL

Aaron M Goodman, MD, Kimberly A Holden, Ah-Reum Jeong, MD, Lisa Kim, Kerry D Fitzgerald, PhD, Eyad Almasri, PhD, Graham McLennan, Marcia Eisenberg, PhD, Amin H Jahromi, Carl Hoh, Michael Hurley, Carolyn Mulroney, MD, Dimitrios Tzachanis, MD PhD, Edward D. Ball, MD, Taylor J Jensen, PhD BS, Razelle Kurzrock, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141010

Published: 2020

Journal Articles

Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies

Sean D Thomas, BS, Ah-Reum Jeong, MD, Patrick J Sakowski, AS, BA, Ethan S Sokol, PhD, Razelle Kurzrock, MD, Aaron M Goodman, MD

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-134375

Published: 2020

Journal Articles

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, MD PhD, Harsh Patel, BS, Vaijayanthi Kandadai Raghavan, Aaron Goodman, Tamara G. Barnes, Razelle Kurzrock, MD

Blood (2019) 134 (Supplement_1): 2319.

https://doi.org/10.1182/blood-2019-126342

Published: 2019

Journal Articles

Genomic Sequencing Reveals Complex and Actionable Molecular Profiles across Hematologic Malignancies

Natalie Galanina, MD, Catriona Jamieson, MD PhD, Razelle Kurzrock, MD

Blood (2018) 132 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2018-99-119877

Published: 2018

Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

Andres Forero-Torres, MD, Seth Rosen, MD, David C. Smith, MD, Glenn Lesser, MD, Julio Peguero, MD, Shilpa Gupta, MD, Justin M. Watts, MD, Marcus Noel, MD, Razelle Kurzrock, MD, Haeseong Park, MD, Patricia LoRusso, DO, Catherine C. Coombs, MD, Fred Zheng, MD, Julie Switzky, RN, Swamy Yeleswaram, PhD, Gerald Falchook, MD

Blood (2017) 130 (Supplement 1): 4048.

https://doi.org/10.1182/blood.V130.Suppl_1.4048.4048

Published: 2017

Journal Articles

HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review

David C Fajgenbaum, MD MSc, Amy Liu, Jason Ruth, PhD, Chris Nabel, PhD, Brian Finkelman, BS, Razelle Kurzrock, MD, Frits van Rhee, MD PhD, Arthur Rubenstein, MBBCh

Blood (2014) 124 (21): 4861.

https://doi.org/10.1182/blood.V124.21.4861.4861

Published: 2014

Journal Articles

Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

David M. Hyman, MD, Eli Diamond, Cecile Rose Vibat, Latifa Hassaine, Jason Poole, Minal Patel, Veronica Holley, Goran Cabrilo, Timothy T. Lu, Maria Arcila, MD, Young Rock Chung, MS, Raajit K. Rampal, MD PhD, Funda Meric-Bernstam, MD, Jose Baselga, MD PhD, Razelle Kurzrock, MD, Mark Erlander, Filip Janku, MD PhD, Omar Abdel-Wahab, MD

Blood (2014) 124 (21): 1833.

https://doi.org/10.1182/blood.V124.21.1833.1833

Published: 2014

Journal Articles

Siltuximab Reverses Muscle Wasting In Patients With Multicentric Castleman’s Disease

Marcotte Kirk, Razelle Kurzrock, MD, Frits van Rhee, MD, PhD, Qi Ming, MD Ph.D, Jessica Vermeulen, Vickie E Baracos, Ph.D, Sunita Ghosh, Ph.D, Michael Sawyer, MD

Blood (2013) 122 (21): 4394.

https://doi.org/10.1182/blood.V122.21.4394.4394

Published: 2013

Journal Articles

Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Lanyi Xie, PhD, Lilian Y Li, PhD, Razelle Kurzrock, MD, Frits van Rhee, MD, PhD, Xiang Qin, MS, Manjula Reddy, MS, Ming Qi, MD, PhD, Hugh M Davis, PhD, Honghui Zhou, PhD, Thomas A Puchalski, PharmD

Blood (2012) 120 (21): 1365.

https://doi.org/10.1182/blood.V120.21.1365.1365

Published: 2012

Journal Articles

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Razelle Kurzrock, MD, Peter M. Voorhees, MD, Corey Casper, MD, Richard R. Furman, MD, Luis Fayad, MD, Sagar Lonial, MD, Hossein Borghaei, DO, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Saad Usmani, MD, FACP, Helgi van de Velde, MD, PhD, Xiang Qin, PhD, Ming Qi, MD, PhD, Mark J. Cornfeld, MD, MPH, Frits van Rhee, MD, PhD

Blood (2011) 118 (21): 3959.

https://doi.org/10.1182/blood.V118.21.3959.3959

Published: 2011

Journal Articles

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.

Frits Van Rhee, MD, PhD, Luis Fayad, MD, Peter Voorhees, MD, Richard R Furman, MD, Hossein Borghaei, DO, MS, Sagar Lonial, MD, Lubomir Sokol, MD, PhD, Julie Crawford, BS, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Jennifer Herring, RN, Xiang Qin, MS, Razelle Kurzrock, MD

Blood (2008) 112 (11): 1008.

https://doi.org/10.1182/blood.V112.11.1008.1008

Published: 2008

Journal Articles

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.

Razelle Kurzrock, MD, Luis Fayad, Peter Voorhees, MD, Richard R Furman, MD, Sagar Lonial, MD, Hossein Borghaei, DO, MS, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Trina Jiao, MS, Jennifer Herring, RN, Xiang Qin, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 1009.

https://doi.org/10.1182/blood.V112.11.1009.1009

Published: 2008

Journal Articles

Clinical Outcomes and Factors Predicting Development of Venous Thromboembolic Complications in Patients with Advanced Refractory Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience

Apostolia-Maria Tsimberidou, MD, PhD, Sushma Vemulapalli, MD, Lakshmi Chintala, MD, Navjot Dhillon, MD, Xiudong Lei, PhD, David Hong, MD, Razelle Kurzrock, MD, Investigational Cancer Therapeutics, M.D.

Blood (2008) 112 (11): 3828.

https://doi.org/10.1182/blood.V112.11.3828.3828

Published: 2008

Journal Articles

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Paul A. Hamlin, MD, Carol Aghajanian, M.D., David Hong, M.D., Anas Younes, M.D., Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Matthew A. Spear, MD, Razelle Kurzrock, MD

Blood (2008) 112 (11): 4939.

https://doi.org/10.1182/blood.V112.11.4939.4939

Published: 2008

Journal Articles

Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.

Apostolia-Maria Tsimberidou, MD, PhD, Elihu Estey, MD, Maher Albitar, MD, Sijin Wen, MS, Mark Brandt, BS, Sherry Pierce, RN, Hagop Kantarjian, MD, Razelle Kurzrock, MD

Blood (2007) 110 (11): 4263.

https://doi.org/10.1182/blood.V110.11.4263.4263

Published: 2007

Journal Articles

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Razelle Kurzrock, MD, Paul Hamlin, M.D., Anas Younes, M.D., David Hong, M.D., Michael Gordon, M.D., Matthew A. Spear, M.D., Michael A. Palladino, Ph.D., G. Kenneth Lloyd, Ph.D., Angie M. Longenecker, R.N., Saskia T.C. Neuteboom, Ph.D., Gillian F. Cropp, M.S., Alison Hannah, M.D., Carol Aghajanian, M.D.

Blood (2007) 110 (11): 4504.

https://doi.org/10.1182/blood.V110.11.4504.4504

Published: 2007

Journal Articles

CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.

Frits VanRhee, MD, PhD, FRCPath, MRCP, Luis Fayad, MD, Hossein Borghaei, OD, MS, Peter M. Voorhees, MD, Robert Z. Orlowski, MD,PhD, Richard R. Furman, MD, Mohamed Zaki, MD,PhD, Uma Prabhakar, Trina Jiao, Christine Lihou, Carlos A. Garay, MD, Razelle Kurzrock, MD, FACP

Blood (2006) 108 (11): 2728.

https://doi.org/10.1182/blood.V108.11.2728.2728

Published: 2006

Journal Articles

Cutaneous T Cell Lymphoma: Responses in Phase 1 Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine.

Navneet Dhillon, MD, Srinivasa Bakkannagari, MD, Chaan Ng, MD, Joann Lim, PharmD, Madeline Duvic, MD, Razelle Kurzrock, MD

Blood (2006) 108 (11): 2466.

https://doi.org/10.1182/blood.V108.11.2466.2466

Published: 2006

Journal Articles

Epstein-Barr Virus in Patients with Chronic Lymphocytic Leukemia.

Apostolia-Maria Tsimberidou, MD, PhD, Michael J. Keating, MD, Carlos Bueso-Ramos, MD, PhD, Razelle Kurzrock, MD, FACP

Blood (2005) 106 (11): 2113.

https://doi.org/10.1182/blood.V106.11.2113.2113

Published: 2005

Journal Articles

A Phase I/II Study of the Oral mTOR Inhibitor RAD001 in Patients with Advanced Hematologic Malignancies.

Karen W.L. Yee, MD, William Wierda, MD, Susan O’Brien, MD, Deborah Thomas, MD, Razelle Kurzrock, MD, Luis E. Fayad, MD, Fredrick B. Hagemeister, MD, Jorge Cortes, MD, Judith Prestifilippo, MD, Ted P. Szatrowski, MD, Hagop M. Kantarjian, MD, Francis J. Giles, MD

Blood (2004) 104 (11): 4818.

https://doi.org/10.1182/blood.V104.11.4818.4818

Published: 2004

NARROW

Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL

Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Genomic Sequencing Reveals Complex and Actionable Molecular Profiles across Hematologic Malignancies

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review

Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

Siltuximab Reverses Muscle Wasting In Patients With Multicentric Castleman’s Disease

Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.

Clinical Outcomes and Factors Predicting Development of Venous Thromboembolic Complications in Patients with Advanced Refractory Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.

Cutaneous T Cell Lymphoma: Responses in Phase 1 Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine.

Epstein-Barr Virus in Patients with Chronic Lymphocytic Leukemia.

A Phase I/II Study of the Oral mTOR Inhibitor RAD001 in Patients with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only